Skip to main content
SpringerLink
Log in

Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2)

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Hyperlipidemia is a well-known risk factor for atherosclerosis and statins are widely used to treat patients with elevated levels of lipids in their plasma. Notwithstanding the proven benefits of statin drugs on both primary and secondary prevention of heart disease, the high cost of statin treatment, in addition to possible side effects such as liver function abnormalities, may limit their widespread use. We conducted a study on a natural product as an alternative to statin treatment. Cholestin, a dietary supplement, is prepared from rice fermented with red yeast (Monascus purpureus), which has been shown to significantly decrease total cholesterol levels in hyperlipidemic subjects. Our objective was to determine the cellular effect of Cholestin on cholesterol synthesis in human hepatic cells (HepG2) and the mechanism by which it caused a change in lipid metabolism. Cholestin had a direct inhibitory effect on HMG-CoA reductase activity (78–69% of control). Cholesterol levels in HepG2 cells treated with Cholestin (25–100 μg/mL) were significantly reduced in a dose-dependent manner (81–45% of control, respectively). This reduction was associated with decreased synthesis and secretion of both unesterified cholesterol (54–31 and 33–14% of control, respectively) and cholesteryl ester (18–6 and 37–19% of control, respectively). These results indicate that one of the anti-hyperlipidemic actions of Cholestin is a consequence of an inhibitory effect on cholesterol biosynthesis in hepatic cells and provide the first documentation of a biomolecular action of red yeast rice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389, 1994

  2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301–1307, 1995

    Google Scholar 

  3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009, 1996

    Google Scholar 

  4. Alberts AW: Lovastatin and simvastatin - inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology 77(suppl 4): 14–21, 1990

    Google Scholar 

  5. Beisiegel U: Lipoprotein metabolism. Eur Heart J 19(suppl A): A20–A23, 1998

    Google Scholar 

  6. Fielding CJ, Fielding PE: Intracellular cholesterol transport. J Lipid Res 38: 1503–1521, 1997

    Google Scholar 

  7. Lehmann EL: Nonparametrics: Statistical Methods Based on Ranks. Holden-Day, San Francisco, 1975

    Google Scholar 

  8. Perreault S, Hamilton VH, Lavoie F, Grover S: Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective? Arch Int Med 158: 375–381, 1998

    Google Scholar 

  9. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VLW: Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69: 231–236, 1999

    Google Scholar 

  10. Stuart MD: Chinese material medica-vegetable kingdom. Southern Materials Centre, Inc., Taipei, 1979

    Google Scholar 

  11. O K, Lynn EG, Chung YH, Siow YL, Man RYK, Choy PC: Homocysteine stimulates the production and secretion of cholesterol in hepatic cells. Biochim Biophys Acta 1393: 317–324, 1998

    Google Scholar 

  12. Wilce PA, Kroon PA: Assay of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase: In: C.A. Converse, E.R. Skinner (eds). Lipoprotein Analysis. A Practical Approach. IRL Press, Oxford, 1992, pp 303–314

    Google Scholar 

  13. O K, Choy PC: Effects of fasting on phosphatidylcholine biosynthesis in hamster liver: Regulation of choline phosphotransferase activity by endogenous argininosuccinate. Biochem J 289: 727–733, 1993

    Google Scholar 

  14. Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program. Second report of the Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). I. Classification, prevalence, detection, and evaluation. Circulation 89: 1344–1363, 1432-1445, 1994

    Google Scholar 

  15. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801–809, 1993

    Google Scholar 

  16. Faruqui RM, DiCorleto PE: Mechanisms of monocyte recruitment and accumulation. Br Heart J 69(suppl): S19–S29, 1993

    Google Scholar 

  17. Raines EW, Ross R: Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69(suppl): S30–S37, 1993

    Google Scholar 

  18. Berlin JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ: Atherosclerosis: Basic mechanisms, oxidation, inflammation, and genetics. Circulation 91: 2488–2496, 1995

    Google Scholar 

  19. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Am J Cardiol 74: 667–673, 1994

    Google Scholar 

  20. Greenspan P, Yu H, Mao F, Gutman RL: Cholesterol deposition in macrophages: Foam cell formation mediated by cholesterol-enriched oxidized low density lipoprotein. J Lipid Res 38: 101–109, 1997

    Google Scholar 

  21. Havel RJ: Dietary supplement or drug? The case of Cholestin. Am J Clin Nutr 69: 175–176, 1999

    Google Scholar 

  22. Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, Bacon SR, Bolognese JA, Frost PH, Lamkin GE: Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia: A multicenter study. Ann Int Med 107: 609–615, 1987

    Google Scholar 

  23. Miettinen TA, Gylling H: Regulation of cholesterol metabolism by dietary plant sterols. Curr Opin Lipid 10: 9–14, 1999

    Google Scholar 

  24. Jones PJ, Ntanios F: Comparable efficacy of hydrogenated vs. nonhydrogenated plant sterol esters on circulating cholesterol levels in humans. Nutr Rev 56: 245–248, 1998

    Google Scholar 

  25. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ: Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 268: 11230–11238, 1993

    Google Scholar 

  26. Lloyd DB, Thompson JF: Transcriptional modulators affect in vivo protein binding to the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase promoters. J Biol Chem 270: 25812–25818, 1995

    Google Scholar 

  27. Funatsu T, Suzuki K, Goto M, Arai Y, Kakuta H, Tanaka H, Yasuda S, Ida M, Nishijima S, Miyata K: Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis 157: 107–115, 2001

    Google Scholar 

  28. Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, Marz W: Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 62: 1545–1555, 2001

    Google Scholar 

Download references

Authors
  1. Ricky Y.K. Man
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward G. Lynn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Filly Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patricia S.Y. Tsang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Karmin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Man, R.Y., Lynn, E.G., Cheung, F. et al. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem 233, 153–158 (2002). https://doi.org/10.1023/A:1017487815091

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1017487815091

Search

Navigation